Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03186118
Previous Study | Return to List | Next Study

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03186118
Recruitment Status : Recruiting
First Posted : June 14, 2017
Last Update Posted : March 27, 2020
Sponsor:
Information provided by (Responsible Party):
Rebecca Gardner, Seattle Children's Hospital

Brief Summary:
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.

Condition or disease Intervention/treatment Phase
CD 19+ Acute Leukemia Biological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC) Phase 1

Detailed Description:
This pilot study seeks to examine the feasibility and safety of administering T cell antigen presenting cells (T-APCs) designed to reactivate and numerically expand CD19-specific CAR T cells. The underlying hypothesis to be examined is that after remission is achieved with CAR T cell treatment, the duration, magnitude, and activation state of persisting memory CAR T cells impact on the potential for durable leukemia eradication. This is of particular relevance in two groups of patients we have identified: those who are predicted to lose persistence of their CAR T cells before Day 63, and those who have definitively lost persistence of CAR T cells prior to 6 months. By providing these patients with episodic exposure to T-APCs capable of activating CD19-specific CAR T cells for proliferation and redistribution to tissue beds where tumor cells of ALL seed, ideally over several months following remission induction, it is posited that the incidence of disease relapse will be diminished.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects are assessed during the parent study for total CD 19 load in bone marrow. Participants meeting eligibility criteria are transitioned into one of 3 arms in PLAT-03.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia
Actual Study Start Date : August 4, 2017
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2033

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia

Arm Intervention/treatment
Experimental: Cohort A
Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
Biological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Name: CD19+ Chimeric Antigen Receptor T-cells (CAR-T cells)

Experimental: Cohort B
Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
Biological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Name: CD19+ Chimeric Antigen Receptor T-cells (CAR-T cells)

Experimental: Cohort C
Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
Biological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Name: CD19+ Chimeric Antigen Receptor T-cells (CAR-T cells)

Experimental: Cohort D
Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
Biological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Other Name: CD19+ Chimeric Antigen Receptor T-cells (CAR-T cells)




Primary Outcome Measures :
  1. The adverse events associated with one or multiple CD19t T-APC product infusions will be assessed. [ Time Frame: up to 6 months ]
    Type, frequency, severity, and duration of adverse events will be summarized

  2. Determine the feasibility of deriving and administering a CD19t T-APC product [ Time Frame: 28 days ]
    Proportion of products successfully manufactured and infused


Secondary Outcome Measures :
  1. Quantification of changes in the number of CAR T cells in peripheral blood before and after receiving CD19t T-APCs [ Time Frame: 6 months ]
    Multiparameter Flow Cytometry (MPF) from peripheral blood as a measure of magnitude and presence of CAR T cells before and after a dose of T-APCs

  2. Duration of B cell aplasia in CD19t T-APC treated patients [ Time Frame: up to 5 years ]
    MPF from peripheral blood as a measure of B cell aplasia



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of recurrent or refractory CD19+ leukemia
  • Adequate performance status
  • Able to tolerate apheresis, including placement of temporary apheresis line if required
  • Adequate renal, liver, cardiac, and respiratory function
  • Adequate absolute lymphocyte count
  • HIV negative; Hepatitis B and C negative within 3 months prior to enrollment.

Exclusion Criteria:

  • Evidence of active clinically significant CNS dysfunction
  • Evidence of active malignancy other than CD19+ malignancy
  • Evidence of active GVHD, or on immunosuppressive GVHD therapy within 4 weeks prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03186118


Contacts
Layout table for location contacts
Contact: Colleen Annesley, MD 206-987-2106 CBDCIntake@seattlechildrens.org

Locations
Layout table for location information
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Colleen Annesley, MD    206-987-2106    CBDCIntake@seattlechildrens.org   
Principal Investigator: Colleen Annesley, MD         
Sponsors and Collaborators
Seattle Children's Hospital
Investigators
Layout table for investigator information
Study Chair: Colleen Annesley, MD Seattle Children's Hospital
Layout table for additonal information
Responsible Party: Rebecca Gardner, Associate Medical Director, Immunotherapy Coordinating Center, Seattle Children's Hospital
ClinicalTrials.gov Identifier: NCT03186118    
Other Study ID Numbers: PLAT-03
First Posted: June 14, 2017    Key Record Dates
Last Update Posted: March 27, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rebecca Gardner, Seattle Children's Hospital:
pediatric
young adult
acute lymphoblastic leukemia
CD 19
leukemia
chimeric antigen receptor
T cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Neoplasms by Histologic Type
Neoplasms